Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Concomitant use of monoamine oxidase inhibitor and tyrosine in parenteral nutrition.
Eur J Clin Nutr
March 2024
Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Monoamine oxidase inhibitors (MAOIs) prevent the breakdown of tyramine in the body, and can cause a sudden increase in blood pressure with significant tyramine build up. This phenomenon, when it occurs, is known as tyramine pressor response. It is unknown if tyrosine administered in parenteral nutrition (PN) leads to tyramine build-up with concomitant use of MAOIs.
View Article and Find Full Text PDFThe novel design of an intelligent anti-depression transdermal drug delivery system.
Biomaterials
December 2023
Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Science and Medical Engineering, Southeast University, Nanjing, 210096, China. Electronic address:
Depression is a type of mental disorder with a significant and persistent low mood as the main clinical feature. It is often accompanied by symptoms such as slow thinking, decreased will, loss of appetite, and weight loss. The current treatment methods for depression are mainly medical treatment, psychotherapy, and physical therapy.
View Article and Find Full Text PDFEfficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations.
Eur Neuropsychopharmacol
July 2023
Clinical Section of Psychiatry and Psychology - Department of Neuroscience, Reproductive Sciences, and Odontostomatology, University School of Medicine Federico II, Naples, Italy; Laboratory of Molecular and Translational Psychiatry, University School of Medicine Federico II, Naples, Italy.
Selegiline is an irreversible, selective type-B monoamine oxidase inhibitor (MAOI) approved for Parkison's disease-oral and major depressive disorder-transdermal formulation) resulting in non-selective MAOI activity at oral doses≥20 mg/day. The present systematic review and meta-analysis appraises the evidence of different formulations/dosages of selegiline across different psychiatric conditions. We inquired PubMed/MEDLINE/Cochrane-Central/WHO-ICTRP/Clarivate-WebOfScience and the Chinese-Electronic-Journal Database from inception to 10/26/2022 for selegiline trials involving psychiatric patients.
View Article and Find Full Text PDFThe Prescriber's Guide to the MAOI Diet-Thinking Through Tyramine Troubles.
Psychopharmacol Bull
May 2022
Van den Eynde, External Research Consultant for PsychoTropical Research, NeuraWell Therapeutics, Aristo Pharma GmbH. Gillman, Director of PsychoTropical Research and MAOI Expert Group Convener. Blackwell, Retired Professor and Chair of Psychiatry at the Milwaukee Campus of the University of Wisconsin School of Medicine.
This review article features comprehensive discussions on the dietary restrictions issued to patients taking a classic monoamine oxidase inhibitor (phenelzine, tranylcypromine, isocarboxazid), or high-dose (oral or transdermal) selegiline. It equips doctors with the knowledge to explain to their patients which dietary precautions are necessary, and why that is so: MAOIs alter the capacity to metabolize certain monoamines, like tyramine, which causes dose-related blood pressure elevations. Modern food production and hygiene standards have resulted in large reductions of tyramine concentrations in most foodstuffs and beverages, including many cheeses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!